News Coverage – Gennova Bio

TRENDING NEWS

Gennova Biopharmaceuticals launches paediatric pack size of HAMSYL Junior

With a 1500 IU pack size and a 2.0 mL fill volume, HAMSYL Junior ensures optimal dosing while retaining the same API strength (750 IU/mL), marking a significant stride in providing paediatric patients in India with a specifically designed and accessible treatment.

ETHeatlhworld | March 08, 2024 / 05:49 PM IST

Regulator approves first Omicron-specific mRNA vaccine from India

India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals Ltd, was approved under emergency use guidelines by the Drug Controller General of India late Monday. This comes a year after the company got approval for GEMCOVAC-19, the country’s first m-RNA vaccine against COVID-19

The Hindu | June 20, 2023 / 09:25 PM IST

DCGI grants Emergency Use Authorization to Gennova biopharma’s Omicron-specific covid booster

The mRNA-based vaccine, GEMCOVAC-OM, was developed by Gennova Biopharmaceuticals using the indigenous platform technology, and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC).

TheEconomicTimes | June 20, 2023 / 02:05 PM IST

India’s first mRNA-based Omicron-specific booster vaccine from Pune-based Gennova gets DCGI approval

The vaccine is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant and has demonstrated robust immune responses in phase 3 clinical trials. It is stable at two to eight degrees Centigrade and has been developed using Gennova’s indigenous platform technology, supported under ‘Mission Covid Suraksha’.

Hindustan Times | June 20, 2023 / 10:11 PM IST

AWARDS

Exemplars of Innovation : Breakthrough Innovation of the Year

A top central official has said that India is set to introduce new vaccines that may later be added as boosters to top up protection against Covid-19. Dr NK Arora, chairperson of the National Technical Advisory Group on Immunisation (NTAGI), told TO on Tuesday that two new “made-in-India” vaccines will soon be available on CoWIN – an mRNA shot and an intranasal vaccine. Read more

DBT-Biotech Awards

Dr. Sanjay Singh receives the “DBT-Biotech Product, Process Development and Commercialization award 2019 (under Organization category)” for the development of Tenectase, a 3rd generation thrombolytic glycoprotein for acute ischemic stroke (AlS) from Honourable Minister of Railways and Minister of Commerce and Industry – Shri Piyush Goyal

Gennova mRNA Covid Booster Vaccine Gets Emergency Use Authorisation

Pune-based Gennova Biopharmaceuticals Ltd on Tuesday said its mRNA COVID-19 booster vaccine against the Omicron variant, GEMCOVAC-OM, has received emergency use authorisation from the Drugs Controller General of India. The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield, the company said adding, it is stable at 2-8 C.

NDTV | June 20, 2023 / 07:55 PM IST

India set to roll out two desi Covid vaccines

Pune-based Gennova BioPharmaceuticals, which developed the country’s first mRNA vaccine and has now obtained approval for a mix-and-match booster dose based on the Omicron strain of the Sars-CoV-2 virus, says it can make a new vaccine based on an emerging strain within 100-days, if need be. Speaking to the media, Sanjay Singh, CEO, Gennova said the firm was in discussions with the Coalition for Epidemic Preparedness Innovations (CEPI) on the matter. “Developing a vaccine on any new strain within 100 days is feasible, and globally such discussions are on.

BusinessStandard • June 20, 2023, 08:26 PM IST

Gennova’s Omicron-specific booster vaccine gets DCGI approval

The vaccine, named GEMCOVAC®-OM, is intended for individuals aged 18 years and older as a booster dose. It can be safely administered to individuals who have already received two doses of either Covaxin or Covishield. The vaccine is administered intradermally using a needle-free device, and it remains stable at temperatures between 2-8 °C, due to which it does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment pan India.

CNBCTV • JUNE 20, 2023, 09:28 PM IST

Gennova gets DCGI’s nod for developing Omicron-specific mRNA vaccine

Pune-based Gennova Biopharmaceuticals Limited has received approval from the Central Drugs Standard Control Organization (CDSCO) for conducting a clinical trial of its mRNA vaccine, Gemcovac-19, against the Omicron variant of COVID19.

MoneyControl | October 10, 2022 / 04:12 PM IST

India set to roll out two desi Covid vaccines

A top central official has said that India is set to introduce new vaccines that may later be added as boosters to top up protection against Covid-19. Dr NK Arora, chairperson of the National Technical Advisory Group on Immunisation (NTAGI), told TO on Tuesday that two new “made-in-India” vaccines will soon be available on CoWIN – an mRNA shot and an intranasal vaccine. Read more

ETHealthWorld • September 21, 2022, 06:23 IST

GEMCOVAC-19, India’s first mRNA Covid-19 vaccine, and how it scores over Pfizer, Moderna

Apart from being indigenously developed, the vaccine is available in powdered form without the need to be stored at sub-zero temperatures, making it easy to transport to remote areas…Read more

MoneyControl • JUNE 29, 2022, 02:38 PM IST

Genova Biopharmaceuticals mRNA COVID-19 vaccine receives EUA from DCGI

GEMCOVAC-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world. These vaccines are highly efficacious because of their inherent capacity of being translated into the protein structure inside the cell cytoplasm. Read more…

ETHealthWorld • June 29, 2022, 13:09 IST

Gennova Biopharmaceuticals ready with 7 mn Gemcovac-19 vaccine dosages

Gennova Biopharmaceuticals Ltd on Wednesday said it is ready with 70 lakh dosages of its Gemcovac-19 vaccine, the first indigenously developed mRNA vaccine against COVID-19…Read more

Business Standard • June 29, 2022

Gennova Bio gets US drug patent to treat brain clots

MUMBAI: Decks have been cleared for a more affordable stroke treatment developed by domestic company Genova Biopharmaceuticals – to go global. The Pune-based biotech company has been granted a patent in the US for its version of drug tenecteplase, to treat brain clots (ischemic stroke), the first ever in the world. Till now, drug alteplase has been largely considered the gold standard for treating brain strokes.

The Times of India • Updated: Jul 14, 2018, 06:08 IST